Clinical

7th Annual Digi-Tech Pharma & AI Conference: Registration Now Open - London, United Kingdom - May 28-29, 2024 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 26, 2024
Health Technology, Pharmaceutical, Health, Genomics, Informatics, GMS, Conference, Data science, Medication, Clinical, Drug discovery, Intelligence, Partnership, Internet of things, Blockchain, Value, Artificial intelligence, Science, AI, Digital health, Deep learning, Medicine, Pleasure, Cloud computing, Head, Machine learning, Data management, VPS, Virtual reality, Fine chemical

The "Digi-Tech Pharma & AI 2024" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Digi-Tech Pharma & AI 2024" conference has been added to ResearchAndMarkets.com's offering.
  • The 7th Annual Digi-Tech Pharma & AI conference, a premier Pharmaceutical Technology Conference, brings with it even more interactive sessions, expert speakers, senior professionals and decision makers from leading pharma, bio-tech and healthcare industry.
  • Meet the decision makers, benchmark and learn from real-life use cases to drive organizational change and to understand the new cutting-edge technologies and practical solutions.
  • It gives us a great pleasure in welcoming you to our whole new pharmaceutical technology conference 7th Annual Digi-Tech Pharma & AI 2024.

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Retrieved on: 
Wednesday, March 13, 2024
Alternative Medicine, Mental Health, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, JAMA, Depression, Disability, Conference, BTD, Breakthrough therapy, Massachusetts General Hospital, Inc., Psychiatry, Clinical, Grammatical mood, Appetite, MDD, Data analysis, Patient, Knowledge, Disease, Causality, Sleep, Anhedonia, DNB, DSM-IV codes, MBBS, Suicidal ideation, Behavior, Cognition, Event, Hospital, Drug development, Safety, Injury, Multimedia, Plasma protein binding, Sadness, Lancet, BMJ, Pharmaceutical industry

If approved by the FDA, CYB003 would be the first known adjunctive psychedelic-based therapeutic for the treatment of MDD.

Key Points: 
  • If approved by the FDA, CYB003 would be the first known adjunctive psychedelic-based therapeutic for the treatment of MDD.
  • The designation of CYB003 as a breakthrough therapy acknowledges the significant unmet medical need for more effective treatments of MDD and supports CYB003’s potential for significant improvements over existing therapies.
  • With the robust durability data from our Phase 2 study in hand, we are ready to move forward expeditiously.
  • (2022) Response to acute monotherapy for major depressive disorder in randomized, placebo-controlled trials submitted to the US Food and Drug Administration: individual participant data analysis.

The Clinical and Laboratory Standards Institute Announces the Publication of New Antimicrobial Susceptibility Testing Documents CLSI M100-Ed34, M02-Ed14, and M07-Ed12

Retrieved on: 
Tuesday, March 26, 2024
M11, Quality control, Government, Communication, Doctor of Pharmacy, Clinical, Committee, CLSI, Accreditation, Salmonella, Table, Laboratory, M02, M07, Microbiology, Patient safety, Multimedia, Medical device

MALVERN, Pa., March 26, 2024 /PRNewswire/ -- The Clinical and Laboratory Standards Institute (CLSI) has released a new update of CLSI M100—Performance Standards for Antimicrobial Susceptibility Testing, 34th Edition and revised editions of CLSI M02—Performance Standards for Antimicrobial Disk Susceptibility Tests, 14th Edition and CLSI M07—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 12th Edition .

Key Points: 
  • MALVERN, Pa., March 26, 2024 /PRNewswire/ -- The Clinical and Laboratory Standards Institute (CLSI) has released a new update of CLSI M100—Performance Standards for Antimicrobial Susceptibility Testing, 34th Edition and revised editions of CLSI M02—Performance Standards for Antimicrobial Disk Susceptibility Tests, 14th Edition and CLSI M07—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 12th Edition .
  • The tables presented in CLSI M100 represent the most current information for drug selection, interpretation, and quality control using the procedures defined in CLSI standards CLSI M02 , M07 , and M11 .
  • Users should replace previously published tables with the new edition of CLSI M100 to ensure accurate testing and patient safety.
  • In addition, CLSI will host its annual What's New in the 2024 CLSI Standards for Antimicrobial Susceptibility Testing webinar on 17 April 2024 from 1:00-2:30 PM ET.

BioTRUST Nutrition® Launches Eternal Mind® Featuring Nutricog® as Groundbreaking Dietary Supplement for Cognitive Support

Retrieved on: 
Tuesday, March 26, 2024
Function (mathematics), Gallic acid, Attention, Brain, Ellagic acid, Longevity, Growth, Prevalence, Learning, BDNF, Science, Clinical, Memory, Disease, Name, Eternal, Ageing, Brain-derived neurotrophic factor, Marketing, Homocysteine, PLT, Food, Dietary supplement

MORRISTOWN, N.J., March 26, 2024 /PRNewswire/ -- PLT Health Solutions, Inc. announced BioTRUST Nutrition® LLC, a leading eCommerce-based nutrition brand with a portfolio of high-quality, science-backed products focused on healthy aging and improving healthspan, has introduced a new product targeted at providing brain longevity and cognitive support called Eternal Mind®. The new product features PLT's Nutricog® Cognitive Performance Complex, an ingredient that has been clinically demonstrated to provide significant improvements across multiple cognitive domains, including learning, memory, attention, focus, and executive function, where increases in cognitive speed were seen concurrently with improvements in accuracy while multitasking. In addition, clinical science showed that Nutricog doubled levels brain-derived neurotrophic factor (BDNF), a neuroprotein involved in the brain's ability to adapt to new information.

Key Points: 
  • Eternal Mind is available direct-to-consumer from the BioTRUST Nutrition website ( www.biotrust.com ) and via Amazon.
  • "Brain and cognitive health are a significant concern for many Americans, especially as we age.
  • However, navigating the cognitive supplement market can be challenging due to the prevalence of expensive products with ambiguous 'proprietary blends' and vague claims," Chris Marschall said.
  • According to BioTRUST®, Eternal Mind is backed by the latest science in brain health.

Contract Research Organization (CRO) Market size to grow by USD 63.35 billion from 2024-2028, Market Growth at 12.61% CAGR expected during the forecast period, Technavio

Retrieved on: 
Wednesday, March 20, 2024
ChromeOS, Software as a service, Science, Chronic condition, Infection, Laboratory, Clinical trial, European, USD, Regulation, Obesity, Biotechnology, Risk, Diabetes, CNS, DSM-IV codes, ROW, Contract research organization, Compound annual growth rate, TB, PPD, Central nervous system disease, Neurology, Medicine, Medication, Clinical, Science 37, Research, Acquisition, Cancer, Drug development, HIV/AIDS, DCT, Growth, Cardiology, Software, Messenger, Behavior, PPD, Inc., Malaria, Lung compliance, Fine chemical

By geography, the global contract research organization (cro) market is segmented into North America, Europe, Asia, and Rest of World (ROW).

Key Points: 
  • By geography, the global contract research organization (cro) market is segmented into North America, Europe, Asia, and Rest of World (ROW).
  • The report provides actionable insights and estimates the contribution of all regions to the growth of the global contract research organization (cro) market.
  • Growth of the Contract Research Organization (CRO) Market industry across North America, Europe, Asia, and Rest of World (ROW)
    Gain instant access to 17,000+ market research reports.
  • The global mRNA synthesis raw material market size is estimated to grow by USD 776.45 million at a CAGR of 4.93% between 2023 and 2028.

Veeva Vault EDC Surpasses 1,000 Study Start Milestone

Retrieved on: 
Wednesday, March 20, 2024
ChromeOS, CDB, Organization, Data science, Clinical, Boehringer Ingelheim, Veeva Systems, EDC, Syneos Health, Data management, Health, Pharmaceutical industry

PLEASANTON, Calif., March 20, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Veeva Vault EDC powered more than 1,000 study starts. The increased adoption of Vault EDC is enabling companies to establish a foundation for modern electronic data capture (EDC), including eight of the top 20 biopharmas and two of the top six CROs standardizing on Vault EDC. This underscores the ongoing shift to advanced clinical data management, with one top 20 biopharma recently migrating 25 studies and more organizations switching to Vault EDC for greater efficiency and speed.

Key Points: 
  • PLEASANTON, Calif., March 20, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Veeva Vault EDC powered more than 1,000 study starts.
  • The increased adoption of Vault EDC is enabling companies to establish a foundation for modern electronic data capture (EDC), including eight of the top 20 biopharmas and two of the top six CROs standardizing on Vault EDC.
  • "Veeva Vault EDC simplifies complex data management for faster study builds and streamlined processes," said Richard Young, vice president, clinical data strategy at Veeva.
  • Vault EDC is part of Veeva Vault Clinical Data Management , bringing together EDC and Veeva Clinical Database (CDB) for next-generation clinical data management.

Veeva Vault EDC Surpasses 1,000 Study Start Milestone

Retrieved on: 
Wednesday, March 20, 2024
ChromeOS, CDB, Organization, Data science, Clinical, Boehringer Ingelheim, Veeva Systems, EDC, Syneos Health, Data management, Health, Pharmaceutical industry

BARCELONA, Spain, March 20, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Veeva Vault EDC powered more than 1,000 study starts. The increased adoption of Vault EDC is enabling companies to establish a foundation for modern electronic data capture (EDC), including eight of the top 20 biopharmas and two of the top six CROs standardizing on Vault EDC. This underscores the ongoing shift to advanced clinical data management, with one top 20 biopharma recently migrating 25 studies and more organizations switching to Vault EDC for greater efficiency and speed.

Key Points: 
  • BARCELONA, Spain, March 20, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Veeva Vault EDC powered more than 1,000 study starts.
  • The increased adoption of Vault EDC is enabling companies to establish a foundation for modern electronic data capture (EDC), including eight of the top 20 biopharmas and two of the top six CROs standardizing on Vault EDC.
  • "Veeva Vault EDC simplifies complex data management for faster study builds and streamlined processes," said Richard Young, vice president, clinical data strategy at Veeva.
  • Vault EDC is part of Veeva Vault Clinical Data Management , bringing together EDC and Veeva Clinical Database (CDB) for next-generation clinical data management.

Register Now for the 7th Annual Digi-Tech Pharma & AI Conference: London, United Kingdom - May 28-29, 2024

Retrieved on: 
Friday, March 15, 2024
Genomics, Informatics, GMS, Conference, Data science, Medication, Clinical, Drug discovery, Intelligence, Partnership, Internet of things, Blockchain, Value, Artificial intelligence, Science, AI, Digital health, Deep learning, Medicine, Pleasure, Cloud computing, Head, Machine learning, Data management, VPS, Virtual reality, Fine chemical

DUBLIN, March 15, 2024 /PRNewswire/ -- The "Digi-Tech Pharma & AI 2024" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 15, 2024 /PRNewswire/ -- The "Digi-Tech Pharma & AI 2024" conference has been added to ResearchAndMarkets.com's offering.
  • The 7th Annual Digi-Tech Pharma & AI conference, a premier Pharmaceutical Technology Conference, brings with it even more interactive sessions, expert speakers, senior professionals and decision makers from leading pharma, bio-tech and healthcare industry.
  • Meet the decision makers, benchmark and learn from real-life use cases to drive organizational change and to understand the new cutting-edge technologies and practical solutions.
  • It gives us a great pleasure in welcoming you to our whole new pharmaceutical technology conference 7th Annual Digi-Tech Pharma & AI 2024.

AI or Bye: Revolutionizing Clinical Trials with Cutting-Edge Technology

Retrieved on: 
Tuesday, March 12, 2024
Automation, GCP, Synthetic media, Jeeva, Algorithm, Clinical, Bias, Patient, Research, Strategic planning, Judgement, Trial of the century, Clinical trial, Publication, Investment, Drug development, Artificial intelligence, Data management, Economics, Health, Writing, Medical device

MANASSAS, Va., March 12, 2024 /PRNewswire-PRWeb/ -- Artificial intelligence (AI) is reshaping drug development and patient care, offering groundbreaking potential. Jeeva Clinical Trials is at the forefront of this shift, addressing the healthcare industry's need for more efficient, inclusive, and compliant clinical trials. Led by Dr. Harsha Rajasimha, Jeeva is embedding AI within its clinical trial framework to automate and accelerate the research workflows and patient outcomes.

Key Points: 
  • Jeeva Clinical Trials is revolutionizing drug development by integrating AI and automated workflows into clinical trials, significantly reducing the time and cost of bringing treatments to market.
  • Jeeva Clinical Trials is at the forefront of this shift, addressing the healthcare industry's need for more efficient, inclusive, and compliant clinical trials.
  • Jeeva Clinical Trials: Pioneering a Future of Inclusive, Efficient Healthcare
    Jeeva Clinical Trials is dedicated to reshaping the landscape of clinical research by harnessing AI technology.
  • As Dr. Rajasimha states, "Clinical Trials that are not powered by AI will be replaced by Clinical Trials that are," and Jeeva is at the forefront of this transformative shift.

Latitude Food Allergy Care Announces the Opening of its New San Francisco Clinic; Pacific Heights Clinic is the First-of-its-Kind and Only Clinic in San Francisco Specifically Dedicated to Food Allergy Patients

Retrieved on: 
Wednesday, March 6, 2024
Private practice, Caregiver, Research, Food allergy, Suite, MD, Van Ness Avenue, Omalizumab, Hospital, Parent, Stanford University, Virginia Mason Medical Center, Phoenix Children's Hospital, House, Internal medicine, Immunology, OIT, Clinical, Patient, Duke University, Clinical trial, Pediatrics, Food, Allergy, Shoe, Nursing

As the only clinic in San Francisco dedicated to food allergies, the new space allows Latitude to expand its hours to provide care for more families.

Key Points: 
  • As the only clinic in San Francisco dedicated to food allergies, the new space allows Latitude to expand its hours to provide care for more families.
  • As with all of Latitude's clinics, the newly built clinic is designed specifically for the needs of food allergy patients and their caregivers.
  • The bright, family room-like setting allows patients to connect with other food allergy families that are going through similar experiences.
  • “We are delighted to welcome two exceptional doctors to the Latitude Food Allergy Care family to expand access to life-changing food allergy care in the San Francisco Bay Area,” said Dr. Rani Maskatia, Medical Director of Latitude Food Allergy Care.